Neurology Academy Published Updated Migraine Guidelines

The new guidance emphasizes CGRP inhibitors for patients experiencing four or more migraine days per month.

Updated on Sept. 24, 2026 in Stroke

Bold flat-color editorial illustration of a glass and steel brain silhouette, representing updated clinical neurological guidelines. — The American Academy of Neurology released its first major update to migraine treatment guidelines since 2012, recommending new preventive pharmaceutical interventions. AI Illustration. Upload story photo >

Live Poll

Do you believe updated medical guidelines improve the quality of care you receive?

The American Academy of Neurology has released updated treatment guidelines for migraine care, marking the first major revision since 2012. The protocols now recommend preventive treatment for patients reporting four or more migraine days each month.

Why it matters

These updates reflect the evolving medical understanding of migraine as a distinct neurological disease. By standardizing care, the organization aims to improve outcomes for a condition that affects approximately 1 billion people worldwide.

The new guidelines explicitly support CGRP inhibitor medications as a first-line preventive strategy for qualified patients. Physicians are further advised to assess the efficacy of Botox treatments after a 24-week period.

The players

American Academy of Neurology

This is a professional medical association representing neurologists and neuroscience professionals dedicated to improving patient care.

The details

The updated framework emphasizes shared decision-making between physicians and patients to tailor treatment plans effectively. These clinical instructions provide a structured approach to managing chronic migraine symptoms through modern pharmaceutical interventions.

The previous migraine treatment guidelines were originally published in 2012.
The American Academy of Neurology published its updated guidelines in September 2026.

The Big Picture

This release updates the clinical standards previously established by the 2012 protocols set forth by the organization. The change represents a significant shift in how the medical community approaches migraine as a chronic neurological disease.

Patients who suffer from four or more migraines monthly may now be eligible for new preventive medication options. Individuals currently receiving Botox should consult their physician regarding the recommended 24-week evaluation timeline.

The takeaway

Patients should engage in shared decision-making with their neurologists to determine if they meet the criteria for new preventive therapies. Maintaining a consistent log of migraine frequency can help physicians accurately assess whether treatment thresholds are met.